Contact
Please use this form to send email to PR contact of this press release:
Onconova Announces Successful End-of-Phase 2 Meeting with FDA for Oral Rigosertib and Azacitidine Combination
TO:
Please use this form to send email to PR contact of this press release:
Onconova Announces Successful End-of-Phase 2 Meeting with FDA for Oral Rigosertib and Azacitidine Combination
TO: